MedTrace Logo

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

NCT06357806 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-03-18

No results posted yet for this study

Summary

This is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.

Conditions

Interventions

DRUG

Sintilimab

100mg/10ml/1bottle

DRUG

Peg-IFNα-2b

180ug/0.5ml/1bottle

DRUG

NAs

tablets

Sponsors & Collaborators

  • Beijing 302 Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-17
Primary Completion
2026-10-08
Completion
2026-10-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06357806 on ClinicalTrials.gov